Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone224-667-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.58 billion
Profitability
Miscellaneous
Employees103,000
Next Earnings Date10/16/2019 (Estimated)
OptionableOptionable
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Friday, June 14th. Shareholders of record on Monday, July 15th will be given a dividend of $0.32 per share on Thursday, August 15th. This represents a $1.28 annualized dividend and a yield of 1.50%. The ex-dividend date of this dividend is Friday, July 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) issued its quarterly earnings data on Wednesday, July, 17th. The healthcare product maker reported $0.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.80 by $0.02. The healthcare product maker earned $7.98 billion during the quarter, compared to analyst estimates of $8 billion. Abbott Laboratories had a net margin of 9.36% and a return on equity of 17.26%. The business's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 EPS. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its FY19 earnings guidance on Wednesday, July, 17th. The company provided EPS guidance of $3.21-3.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.22.
What price target have analysts set for ABT?
18 brokers have issued 1 year target prices for Abbott Laboratories' shares. Their predictions range from $68.00 to $98.00. On average, they anticipate Abbott Laboratories' share price to reach $85.94 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
Has Abbott Laboratories been receiving favorable news coverage?
News coverage about ABT stock has trended somewhat positive on Tuesday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Abbott Laboratories earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news articles about the healthcare product maker a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Abbott Laboratories.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).
What other stocks do shareholders of Abbott Laboratories own?
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
- Mr. Robert B. Ford, Pres & COO (Age 45)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.39%), BlackRock Inc. (7.16%), Northern Trust Corp (1.50%), Bank of New York Mellon Corp (1.25%), Morgan Stanley (1.19%) and Janus Henderson Group PLC (0.96%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which institutional investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Primecap Management Co. CA, Westwood Holdings Group Inc., Morgan Stanley, UBS Asset Management Americas Inc., Waddell & Reed Financial Inc. and Poplar Forest Capital LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which institutional investors are buying Abbott Laboratories stock?
ABT stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Vanguard Group Inc., BlackRock Inc., Marshall Wace North America L.P., Thoroughbred Financial Services LLC, DekaBank Deutsche Girozentrale, Voleon Capital Management LP and Investec Asset Management LTD. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $85.56.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $151.22 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.
What is Abbott Laboratories' official website?
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
